The following is an excerpt from a recent scientific publica…

The following is an excerpt from a recent scientific publication:“Covalent inhibitors can achieve exquisite potency and durable target occupancy through a combination of covalent and noncovalent interactions. Drugs that possess a covalent mechanism‑of‑action encompass recent blockbusters (Clopidogrel) as well as early cornerstones of modern medicine (aspirin and penicillin). Despite this well‑documented history and the advantages from sustained target engagement, pharmaceutical companies have traditionally shied away from covalent drug programs due to concerns about potential idiosyncratic toxicity. However, clinical successes over the past decade (e.g. Ibrutinib), along with improvements in technologies used throughout the drug discovery pipeline, have reignited broad interest in this class of therapeutics.” What key advantage of covalent inhibitors is emphasized here in drug discovery?